Dendrimer and cancer: a patent review (2006-present)

被引:33
作者
Cai, Xiaopan [3 ,4 ]
Hu, Jingjing [5 ]
Xiao, Jianru [3 ]
Cheng, Yiyun [1 ,2 ]
机构
[1] E China Normal Univ, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China
[2] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China
[3] Second Mil Med Univ, Changzheng Hosp, Dept Orthoped Oncol, Shanghai 200003, Peoples R China
[4] First Peoples Hosp Hefei City, Binhu Hosp, Dept Orthoped, Hefei 230001, Peoples R China
[5] Dalian Univ Technol, Dept Biosci & Biotechnol, Dalian 116024, Peoples R China
关键词
anti-cancer drug; cancer; cancer therapy; dendrimer; diagnosis; targeting; BIOMEDICAL APPLICATIONS; DELIVERY; DESIGN;
D O I
10.1517/13543776.2013.761207
中图分类号
R914 [药物化学];
学科分类号
100705 [微生物与生化药学];
摘要
Introduction: Dendrimers were widely used in cancer diagnosis and therapy during the past decade. The surface functionalities allow bioactive molecules such as imaging probes, therapeutic compounds, targeting ligands to be present on dendrimer surface in a multivalent fashion. In addition, the interior pockets as well as the charged surface of dendrimer can be encapsulated/bound with anti-cancer drugs or therapeutic DNAs/siRNAs. Areas covered: The combination of dendrimer chemistry and new cancer therapy techniques such as radiotherapy, photodynamic therapy, neuron capture therapy, and photothermal therapy provides promising strategies in future cancer therapy. Here, we focused on recent advances on this topic in the patents (2006 - present) and discussed the advantages of dendrimer technology in these inventions. Expert opinion: The challenges and perspectives of dendrimer-based theranostics for cancer diagnosis and therapy are discussed. Future efforts in this area should be focused on designing materials to solve problems such as cancer metastasis, multidrug resistance (MDR) in cancer cells, and early-stage cancer diagnosis.
引用
收藏
页码:515 / 529
页数:15
相关论文
共 101 条
[1]
Agrez MV, 2009, Therapeutic peptides, Patent No. [WO103127, 103127]
[2]
Albrecht V., 2012, Photo-triggered release of active substances from dendrimer-photosensitizer complexes, Patent No. [US8153111, 8153111]
[3]
Babich JW, 2012, Psma-targeted dendrimers, Patent No. [WO078534, 078534]
[4]
Baker Jr. J.R., 2010, Dendrimer conjugates, Patent No. [US20100160299, 20100160299, 2010/0160299]
[5]
Baker Jr J.R., 2010, Dendrimer based modular platforms, Patent No. [US20100158850, 20100158850]
[6]
Baker Jr J.R., 2009, Dendrimer based compositions and methods of using the same, Patent No. [US20090088376, 20090088376]
[7]
Baker Jr JR, 2012, Synthesis of dendrimer conjugates, Patent No. [US2012/0177593, 20120177593]
[8]
Baker Jr JR, 2012, Dendrimer compositions and methods of synthesis, Patent No. [US20120259098, 20120259098]
[9]
Baker Jr JR, 2009, Dendrimer based compositions and methods of using the same, Patent No. [WO009203, 009203]
[10]
Baker Jr JR, 2012, Synthesis and isolation of dendrimer systems, Patent No. [US20120232225, 20120232225]